Butantan Institute
Butantan Institute
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB) | Dengue Fever With Warning Signs | Not yet recruiting | Phase 3 | 2026-07-20 | NCT07712926 | |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases | Aortic Arch Syndromes, Axial Spondyloarthritis, Cerebral Small Vessel Diseases, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, Takayasu arteritis, ankylosis, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, aortic disorder, arteritis, arthritic joint disease, arthropathy, autoimmune disease, bone disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, connective tissue disorder, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, juvenile idiopathic arthritis, lung disorder, microscopic polyangiitis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nervous system disorder, neuromuscular disease, psoriasis, psoriatic arthritis, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, skin disorder, skin vascular disease, spondylitis, systemic lupus erythematosus, systemic sclerosis, vascular disorder, vasculitis, vertebral column disorder | Recruiting | Phase 4 | 2026-07-20 | NCT07087912 | |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. | Alphavirus infectious disease, Flaviviridae infectious disease, Flavivirus Infections, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, dengue disease, vector-borne disease, viral hemorrhagic fever, viral infectious disease | Not yet recruiting | Phase 3 | 2026-07-16 | NCT06973772 | |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) | Flaviviridae infectious disease, Flavivirus Infections, Infections, Mosquito-Borne Diseases, RNA Virus Infections, arbovirus infection, dengue disease, vector-borne disease, viral hemorrhagic fever, viral infectious disease | Recruiting | Phase 3 | 2026-07-16 | NCT06891950 | |
| Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults | Infections, RNA Virus Infections, avian influenza, bird disease, influenza, non-human animal disease, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-04-02 | NCT06842173 |